Genentech's Hemlibra meets in Phase III for hemophilia A

The Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) said subcutaneous Hemlibra emicizumab-kxwh as prophylaxis met the primary endpoint in the Phase III HAVEN 3 trial to treat hemophilia A patients ages 12 and older without inhibitors to Factor VIII.

Last week, FDA approved once-weekly subcutaneous Hemlibra for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and children with hemophilia A with Factor VIII inhibitors (see BioCentury Extra, Nov. 16)...